Utero-vaginal aplasia (Mayer-Rokitansky-Küster-Hauser syndrome) associated with deletions in known DiGeorge or DiGeorge-like loci by Morcel, Karine et al.
RESEARCH Open Access
Utero-vaginal aplasia (Mayer-Rokitansky-Küster-
Hauser syndrome) associated with deletions in
known DiGeorge or DiGeorge-like loci
Karine Morcel
1,2*†, Tanguy Watrin
1†, Laurent Pasquier
1,3, Lucie Rochard
1, Cédric Le Caignec
4,5, Christèle Dubourg
1,6,
Philippe Loget
7, Bernard-Jean Paniel
8, Sylvie Odent
1,3, Véronique David
1,6, Isabelle Pellerin
1, Claude Bendavid
1,6
and Daniel Guerrier
1
Abstract
Background: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is characterized by congenital aplasia of the uterus
and the upper part of the vagina in women showing normal development of secondary sexual characteristics and
a normal 46, XX karyotype. The uterovaginal aplasia is either isolated (type I) or more frequently associated with
other malformations (type II or Müllerian Renal Cervico-thoracic Somite (MURCS) association), some of which
belong to the malformation spectrum of DiGeorge phenotype (DGS). Its etiology remains poorly understood. Thus
the phenotypic manifestations of MRKH and DGS overlap suggesting a possible genetic link. This would potentially
have clinical consequences.
Methods: We searched DiGeorge critical chromosomal regions for chromosomal anomalies in a cohort of 57
subjects with uterovaginal aplasia (55 women and 2 aborted fetuses). For this candidate locus approach, we used a
multiplex ligation-dependent probe amplification (MLPA) assay based on a kit designed for investigation of the
chromosomal regions known to be involved in DGS.
The deletions detected were validated by Duplex PCR/liquid chromatography (DP/LC) and/or array-CGH analysis.
Results: We found deletions in four probands within the four chromosomal loci 4q34-qter, 8p23.1, 10p14 and
22q11.2 implicated in almost all cases of DGS syndrome.
Conclusion: Uterovaginal aplasia appears to be an additional feature of the broad spectrum of the DGS
phenotype. The DiGeorge critical chromosomal regions may be candidate loci for a subset of MRKH syndrome
(MURCS association) individuals. However, the genes mapping at the sites of these deletions involved in
uterovaginal anomalies remain to be determined. These findings have consequences for clinical investigations, the
care of patients and their relatives, and genetic counseling.
Background
Congenital aplasia of the uterus and the upper two thirds
of the vagina is diagnosed as Mayer-Rokitansky-Küster-
Hauser (MRKH) syndrome in 90% of affected women
presenting with primary amenorrhea and otherwise nor-
mal secondary sexual characteristics, normal ovaries and
a normal karyotype (46, XX) [1]. The incidence of
MRKH syndrome has been estimated to be 1 in 4500
female births [2-4]. The uterovaginal aplasia can be iso-
lated (type I; OMIM 277000) but it is more frequently
associated with other malformations (type II; OMIM
6601076). Type II is also referred to as the MURCS
(Müllerian Renal Cervico-thoracic Somite anomalies)
association. The most common associated malformations
involve the upper urinary tract affecting about 40% of
patients [5] and the cervicothoracic spine affecting about
30 to 40% of patients [5-7]. Renal malformations include
unilateral agenesis, ectopia of one or both kidneys, horse-
shoe kidney, hydronephrosis [7], and even bilateral renal
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most commonly encountered are scoliosis, isolated ver-
tebral anomalies (asymmetric, fused or wedged verteb-
rae), Klippel-Feil association or Sprengel deformity [7,9].
Less frequent associated anomalies include hearing
defects in about 10 to 25% of patients [10,11]. Cardiac
malformations, such as tetralogy of Fallot [12], atrial sep-
tal defect [13] or pulmonary valvular stenosis [14] are
found in rare cases, as rare facial asymmetry [15-17] and
digital anomalies, such as brachymesophalangy, ectrodac-
tyly or duplicated thumb [18-20]. Type II MRKH or the
MURCS association may be attributed to alterations in
the blastema giving rise to the cervicothoracic somites
and the pronephric ducts, the ultimate spatial relation-
ships of which are already determined by the end of the
fourth week of fetal development [21].
MRKH syndrome was initially considered to be spora-
dic. The involvement of non-genetic or environmental
factors was suggested but rejected. The description of
an increasing and significant number of familial cases
confirmed the involvement of a genetic component. The
syndrome appears to be transmitted as an autosomal
dominant trait with incomplete penetrance and variable
expressivity [2,22-24]. Observations are consistent with
a polygenic or multifactorial cause involving either
mutations in one or several major developmental genes
or limited chromosomal imbalances. However, the etiol-
ogy of MRKH syndrome remains poorly understood
(see [1] for review). At the present time, only a SHOX
duplication has been described associated with type I
MRKH syndrome in some cases [25].
In respect to type II MRKH or MURCS association, the
lack of clear genetic or chromosomal evidence led us to
consider the wider spectrum of uterovaginal aplasia-asso-
ciated malformations as a starting point for genetic inves-
tigations. We compared MRKH syndrome with other
syndromes displaying phenotypic features overlapping
with those of MRKH syndrome. Several of the anomalies
found in the MRKH syndrome are also within the clinical
spectrum of the 22q11.2 deletion syndrome, also referred
to as DiGeorge syndrome (DGS syndrome; OMIM
188400) and velocardiofacial syndrome (VCF syndrome;
OMIM 192430). Indeed, this phenotype involves conge-
nital heart defects, such as tetralogy of Fallot, interrupted
aortic arch, ventricular septal defect or persistent troncus
arteriosus, dysmorphic facial features, cleft palate, hear-
ing loss, thymic hypoplasia, hypoparathyroïdism, and
developmental and behavioral problems [26-28]. Other
less common manifestations include renal (horseshoe,
hydronephrosis), vertebral (butterfly vertebrae, hemiver-
tebrae, abnormalities of the cervical spine, scoliosis,
Sprengel deformity) and extremity anomalies (polydac-
tyly, syndactyly, club-foot) [28-30]. Ninety% of cases of
DGS and 70% of cases of VCF syndrome are caused by a
1.5 to 3.0 Mb hemizygous deletion of chromosome
22q11.2 [31]. More precisely, the strictly DiGeorge syn-
drome appears to be associated with only TBX1 deletion
or mutations [32]. However, DGS-like phenotypes have
also been reported in patients with deletions of chromo-
some 4q34.2-qter [33,34], 8p23-pter [34-36], 10p14-p15
[34,37-41], 17p13 [42] or 18q21 [43], chromosomes 4, 8
and 10 being the most frequently chromosomes
described associated with DGS-like phenotype. Some stu-
dies have described MRKH syndrome features associated
with 22q11.2 deletions [8,44-47] and we showed a 4q34-
qter deletion in one case of MRKH syndrome [48].
Here, we report a search in a cohort of 57 patients
affected by the MRKH syndrome for deletions in the
chromosomal regions most frequently associated with
the DGS or the DGS-like phenotypes.
Patients and methods
Patients
We studied 55 women who presented utero-vaginal
aplasia diagnosed by clinical examination and transab-
dominal ultrasonography and/or magnetic resonance
imaging (MRI) or celioscopy. All patients had a normal
46, XX karyotype. The patients underwent a check-up
to search for associated malformations including renal
ultrasonography, spine radiography and echocardiogra-
phy or audiogram, if required. Twenty (36.4%) presented
isolated uterovaginal aplasia (MRKH type I). The other
women (63.6%) variously displayed kidney defects,
vertebral and other skeletal malformations (including
Klippel-Feil and Sprengel anomalies, digital anomalies
such as clinodactyly, brachydactyly and syndactyly), car-
diac anomalies and hearing impairment. Two aborted
fetuses with various abnormalities including uterovaginal
aplasia were also analyzed.
All the subjects were enrolled through a French
national multicentric research program, called PRAM
(Programme de Recherche sur les Aplasies Müllér-
iennes), which is registered in the Orphanet database
(http://orphanet.infobiogen.fr). This study was approved
by the local institutional review board, the “Comité de
Protection des Personnes” (Project # 05/16-543), and is
registered with the French Ministry of Health (DGS #
2005/030). Here, we only report the clinical features of
the four subjects in whom we detected a deletion.
Case 1
This patient presented with primary amenorrhea, lead-
ing to a diagnosis of congenital absence of the upper
vagina and uterus, with normal bilateral adnexa, as con-
firmed by celioscopy. Thelarche and pubarche were nor-
mal. The patient had no visceral malformations (the
heart and kidneys, in particular, were normal, as
assessed by ultrasound examinations) or hearing impair-
ment. No skeletal abnormalities were observed. This
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dard and she was the only daughter of non consangui-
neous parents who suffered one miscarriage. Her father
had no relevant medical background. Her mother was
152 cm tall and was 58 years old at the time of the
study. At birth, the patient’s mother had bilateral club
feet. An atrial septal defect (ostium secundum type) was
subsequently detected, requiring surgical correction at
the age of 23. Bilateral serous carcinoma of the Fallo-
pian tubes was diagnosed four years ago. The patient’s
mother had no renal defects or skeletal abnormalities.
No mental impairment or other visceral malformations
were reported in this family.
Case 2
This 19-year-old female patient was referred for the eva-
luation of primary amenorrhea. Thelarche and adre-
narche had occurred at 13 years of age. Congenital
uterovaginal aplasia with symmetric muscular buds,
bilaterally normal ovaries and Fallopian tubes were
demonstrated by celioscopy. Screening for anomalies
commonly associated with MRKH syndrome revealed
unilateral kidney agenesis but no other defects. In parti-
cular, this patient displayed no deafness or skeletal,
heart, limb and facial malformations. She also had no
psychiatric disorders. This patient had two sisters and
two brothers, none of whom have any malformations.
Her parents were phenotypically normal but were una-
vailable for further investigation. There was no family
history of recurrent abortion or consanguinity.
Case 3
Case 3 was a fetus from a medically terminated preg-
nancy at 18 weeks of gestation following the ultrasono-
graphic discovery of a bilateral renal agenesis.
Fetopathological examination confirmed the absence of
kidneys associated with uterovaginal aplasia. No other
skeletal or heart malformation was observed. We later
established that the father and the two sisters also dis-
played unilateral renal agenesis, without associated heart
or skeletal malformation. Fetal ultrasound of the two
sisters did not reveal any uterine malformation but no
genital examination was performed (the children were
too young). Case 3 had a normal 46, XX karyotype. The
mother had no relevant medical history. One of the
first-degree female cousins of the father presented uni-
lateral renal agenesis also associated with ipsilateral half-
uterus.
Case 4
This case was a female fetus obtained following medically
termination of a pregnancy at 23.5 weeks of gestation
due to bilateral renal agenesis. Fetopathological examina-
tion showed, in addition to the bilateral renal agenesis,
uterovaginal aplasia, type B interrupted aortic arch, and
thymic hypoplasia. Neither parent had morphological
anomalies. This case has been preliminarily reported in a
study of 49 fetuses with three or more significant anoma-
lies of unknown etiology, in which a battery of CGH
methods were applied to detect chromosomal imbalances
[49].
Healthy control subjects
About 15% of genes in the OMIM morbid map overlap
CNVs (Redon, 2006). CNVs can cause Mendelian or
sporadic traits, or be associated with complex diseases.
Probands can inherit a disease-associated rearrangement
from unaffected parents, which underscores the variable
penetrance of some diseases resulting from dosage
effects (Redon, 2006). However, CNVs can also be
benign polymorphism variants. To confirm that the
deletions observed in the present cases were not non-
pathogenic genomic copy number variations (CNV), a
cohort of 100 healthy normal subjects (50 men and 50
women) was tested. All volunteers were informed about
the study and signed a consent form approved by the
local Ethical Committee.
Methods
Genomic DNA was extracted from whole blood of
patients or from fetal tissues, whole blood of parents
and healthy control subjects using the QIAamp DNA
Kit (http://www.qiagen.com) according to the manufac-
turer’s protocol.
MLPA
Multiplex ligation-dependent probe amplification
(MLPA) was performed with samples from our cohort
of 57 MRKH syndrome patients, the parents if possible
and 100 healthy control subjects. Two independent
experiments were carried out each on 100ng of genomic
DNA. We used the SALSA MLPA kit P023-DiGeorge
(MRC-Holland, Amsterdam, Netherlands) according to
the manufacturer’s instructions. This kit allows semi-
quantitative analysis of 39 genomic sequences located
on 4q (six targets), 7p15 (one target), 8p (five targets),
10p (five targets), 17p13 (four targets), 18q21 (two tar-
gets), 22q11 (ten targets) and 22q13 (one target); most
of these loci are involved in DGS or DGS-like pheno-
types. Amplification products were analyzed by capillary
electrophoresis using an ABI 3100 Genetic Analyzer
(Applied Biosystems). ABI result files were normalized
using the GeneMarker Software (Softgenetics) and an
in-house Excel spreadsheet. The results are represented
as histograms.
Duplex PCR/liquid chromatography (DP/LC)
The chromosomal breakpoints in cases 2 and 3 were
confirmed and mapped more precisely using multiplex
PCR/liquid chromatography in a duplex assay according
to a standard protocol [50]. Briefly, duplex PCR was
used, associating unlabeled primers for an endogenous
control gene, HMBS,a n df o rt h er e g i o ns h o w i n g
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neous amplification of the two targets under semi-quan-
titative conditions. Primers were designed using Primer
Premier Software (Premier Biosoft International, Palo
Alto, CA, USA). Navigator™ Software (Transgenomic,
Omaha, NE, USA) was used for data analysis and the
HMBS peak was used for normalization; relative peak
intensities for each amplicon directly reflected genomic
copy number.
Array-CGH
Oligonucleotide array-CGH analysis was performed using
the Agilent Human Genome CGH microarray 44 K (Agi-
lent Technologies, Santa Clara, CA, USA) as described in
version 4.0 of the protocol provided by Agilent (Agilent
Oligonucleotide Array-Based CGH for Genomic DNA
Analysis). This platform is constituted of 44,290 60-mer
oligonucleotide probes for mapped genes or unique DNA
sequences with an average spatial resolution of 35 Kb.
Patient and same gender reference genomic DNA
(gDNA) were digested, labeled with Cy5™-dUTP and
Cy3™-dUTP using the Agilent Genomic DNA Labeling
Kit PLUS and cohybridized to Agilent 4 × 44 k arrays.
After washes, hybridized slides were scanned on the Agi-
lent scanner G2565BA. Images were analyzed with Agi-
lent Feature Extraction Software version 9.1 (CGH-v4_91
protocol). Data were imported into Agilent CGH analy-
tics software version 3.4.27 (statistical algorithm: z-score,
sensitivity threshold: 2.5, moving average window: 5
points) for a graphical overview and analysis.
Results
The 57 patients and 100 healthy control subjects were
tested by MLPA with the P023 kit. None of the control
subjects showed variation in the copy number for any of
the markers used in this kit. The analysis disclosed a
deletion at different chromosomal regions in each of four
patients (Figure 1): deletion of three probes (FLJ10474
corresponding to ODZ3 g e n e ,C A S P 3 ,K L K B 1 )a t4 q 3 4 -
qter in case 1; one probe (MSRA gene) at 8p23 in case 2;
one probe (MGC10848 corresponding to ITIH5 gene) at
10p14 in case 3; and seven probes (KIAA1652 and
FLJ14360 corresponding to TXNRD2 and KLHL22 genes,
respectively, HIRA, CLDN5, PCQAP, SNAP29, LZTR1)
at 22q11.2 in case 4.
For case 1, testing with the MLPA P023 kit revealed
an identical deletion of about 8 Mb at 4q34-qter in the
mother, but no deletion was found in the father. A com-
plementary DP/LC analysis, reported previously, corro-
borated these results [48]. We confirmed and refined
this former analysis by array-CGH and demonstrated
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Figure 1 MLPA analysis of cases 1 to 4. Gene dosage in cases 1 to 4 assessed by the MLPA P023 kit. Histogramms represent allelic dosage of
each target gene. Black arrows show deletion of (A) FLJ10474 (ODZ3), CASP3 and KLKB1 probes at 4q34-qter in case 1; (B) MSRA probe at 8p23
in case 2; (C) MGC10848 (ITIH5) probe at 10p14 in case 3; (D) HIRA, CLDN5, KIAA1652 (TXNRD2), FLJ14360 (KLHL22), PCQAP, SNAP29, LZTR1
probes at 22q11.2 in case 4.
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either the proband or her mother, and no abnormality
in her father (Figure 2).
MLPA analysis of case 2 led to detect a single copy of
the MSRA gene on chromosome 8p23 but two copies of
the flanking genes, PPP1R3B and GATA4, were found in
the same MLPA experiment, leading to estimate the
maximum size of the deletion to be 2.6 Mb. The chro-
mosomal breakpoint was more accurately mapped using
DL/PC with amplicons located in TNKS, MSRA (used to
corroborate MLPA results), UNQ9391, RP1L1, SOX7,
PINX genes and in the C8orf74 open reading frame: the
maximum size of the deletion was then found to be 1.2
Mb in between TNKS and UNQ9391 (Figure 3). How-
ever, we could not investigate either this case by array-
CGH (insufficient genomic DNA was available) or her
parents because we were unable to contact the family
again.
MLPA analysis of case 3 revealed a deletion of 0.9 Mb
maximum in the 10p14 region which includes the whole
ITIH5 gene. DP/LC of the SFMBT2 and ITIH2 genes
flanking the ITIH5 gene mapped this deletion to a maxi-
mal size of 230 Kb, including only the ITIH5 gene
(Figure 4A). In addition, array-CGH analysis showed no
deletion of the markers flanking the ITIH5 gene or in
other parts of the genome (data not shown). Thus, this
deletion appears to be very small. MLPA, DP/LC and
array-CGH analysis identified no deletion in the father,
the two sisters, the first-degree paternal female cousin
who presented unilateral renal agenesis, or in the phe-
notypically normal mother and two paternal aunts. The
pedigree of this family is shown in Figure 4B.
MLPA analysis of case 4 confirmed and refined the
preliminary results published on this case. Deletion of
three clustered probes (RP1-157E19, RP1-238C15, and
RP11-316L10) at 22q11.2 was found by array-CGH
and confirmed by QMPSF (Quantitative Multiplex
PCR of Short Fluorescent fragments) (TBX1 amplicon)
[49]. Comparison of the 6.3 Mb deletion initially
found by array-CGH and that of 5.95 Mb we detected
by MLPA indicated that the deletion was 5.24 Mb
maximum.
Discussion
We report four chromosomal deletions located at
4q34-qter, 8p23, 10p14 and 22q11.2, all known to be
associated with DGS or DGS-like phenotypes, in four
independent MRKH subjects.
Case 1 Case 1’s mother Case 1’s father Chr. 4
Figure 2 Array-CGH profile of chromosome 4 in case 1 and her parents. A deletion of about 8 Mb was detected in 4q34-qter in case 1 and
her mother (black boxes). No deletion was found in her father. Log2 ratio values for all probes are plotted as a function of their chromosomal
position. Solid and dotted lines indicate the log2 ratio thresholds -0.25 (loss) and 0.25 (gain), respectively.
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pathogenic chromosomal variants, we first consulted the
Database of Genomic Variants (http://projects.tcag.ca/
variation/) to exclude copy number variations (CNVs)
previously observed in control healthy individuals.
CNVs within each of the loci investigated in our study
were reported to be absent, smaller or very rare (<0.5%).
To distinguish between potentially pathogenic variants
a n du n i d e n t i f i e db e n i g nC N V s ,w et e s t e d1 0 0D N A
samples from healthy volunteers with the same MLPA
kit. No variation in copy number was observed in these
controls for any of the markers used in this kit. The size
of the deletions found in the described cases and the
absence of deletion at these loci from all controls,
strongly suggest that the four deletions we identified are
pathogenic.
Deletion of 4q34-qter may lead to a phenotype similar
to the DiGeorge phenotype [33,34], including congenital
heart disease (atrial septal defect, ventricular septal
defect), cleft palate, and learning difficulties. Few cases
of 4q34-qter deletion have been reported [33,51,52] and
there are only three reports of familial transmission
affecting the mother and her sons showing features of
DiGeorge syndrome [52-54]. The present case 1 is the
fourth described case of familial transmission of 4q34-
qter deletion and the first case associated with MRKH
syndrome inherited from a mother displaying different
clinical features. Several genes are included in this dele-
tion: the FAT tumor suppressor 1 (FAT1)g e n e ,w h i c h
belongs to the cadherin superfamily [55], appears to be
a common candidate gene for malformations observed
in both the daughter and the mother [48]. First, FAT1
has been described as one of the five tumor suppressor
gene located on the long arm of chromosome 4 [56-59]
and was evidenced as an anti-proliferative factor of
smooth muscle cells [60]. So, it might account for the
bilateral serous carcinoma of the Fallopian tubes, discov-
ered in case 1’s mother when she was 54, as previously
discussed [48]. Second, the FAT1 gene appears to be
also a putative candidate gene for a developmental fail-
ure of Müllerian differentiation in the embryo. Indeed,
the protein encoded by this gene has been shown to
take an important part to developmental processes
requiring cell polarization [61], cell-cell interactions [55]
and epithelium-mesenchyme interaction [62] such as
tubulogenesis [63]. In particular, it seems to be involved
in smooth muscle differentiation process [62] and could
therefore give an explanation to the Müllerian duct dif-
ferentiation arrest observed in MRKH syndrome. In this
hypothesis, haploinsufficiency of the FAT1 gene would
lead to unequal consequences, probably depending on
each patient’s genomic background and affecting
embryonic or adult tissues. It may therefore be helpful
for future studies to request further information about
internal genital anomalies and cancer susceptibility in
individuals with 4q deletions.
Small interstitial deletions within the 8p23.1 region,
such as that found in case 2, have been associated with
severe congenital heart disease, mental retardation,
microcephaly, and a characteristic behavioral phenotype,
all these features being included in DGS-like phenotype
[35,36]. The GATA4 gene at 8p23.1-pter has been impli-
cated in all such cases with a heart defect [36,64,65] but
not in patients without heart defects [36]. The region
deleted from our patient mapped close to GATA4,b u t
did not include this gene, consistent with the phenotype
of this patient. Deletion of 8p23.1 has also been shown
to be associated with renal anomalies (hydronephrosis,
horseshoe kidney), vertebral anomalies, and polydactyly
[64-67]. All these features are included in the associated
malformations of type II MRKH (MURCS association)
[1]. This suggests that the different clinical features
observed in case 2 may be caused by the deletion of
Genename
Deleted
MLPA DP/LC
No NA
No NA
NA No
Yes Yes
UNQ9391 NA No
RP1L1 NA No
C8orf74 NA No
SOX7 NA No
PINX1 NA No
GATA4 No NA
ChGn No NA
8p23.1
8 Mb
9 Mb
10 Mb
11 Mb
12 Mb
13 Mb
14 Mb
15 Mb
16 Mb
17 Mb
18 Mb
19 Mb
8p22
MFHAS1
PPP1R3B
TNKS
MSRA
Figure 3 Details of the 8p23 deletion found in case 2. Summary
of gene quantification and chromosome breakpoint refinement:
several genes were tested by MLPA (P023 kit) and DP/LC. The
combined results show an about 1.2 Mb deletion delimited by TNKS
and UNQ9391 gene markers and including MSRA. NA: Not
Applicable.
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that the 8p23.1 chromosomal region corresponding to a
DGS-like morbid locus includes at least one gene
involved in MRKH syndrome. This region contains the
peptide methionine sulfoxide reductase (MSRA)g e n e
[68], the retina-specific RP1L1 gene [69], MIR 124-1, a
micro-RNA preferentially expressed in the developing
brain [70], the TNKS gene involved in regulating telo-
mere length [71], and other genes of unknown function.
None of the known genes in this region is particularly
likely to be involved in MRKH syndrome. Finding redun-
dant deletions in a larger cohort of patients would cer-
tainly be of great help to map the MRKH-associated
genomic region on 8p23.1 and identify candidate gene(s).
Chromosome 10p terminal deletions have also been
associated with DiGeorge-like phenotypes [39,40,72].
Studies of patients with 10p deletions have allowed the
definition of two non-overlapping regions that contri-
bute to this complex phenotype: the DiGeorge critical
region 2 (DGCR2) [39,72] located on 10p13-14 asso-
ciated with heart defects and T-cell deficiency; and the
HDR region located on 10p14-10pter associated with
hypoparathyroïdism, sensorineural deafness, and renal
defect [73]. This implies that the DGS-like phenotype
associated with 10p deletion can be considered as a con-
tiguous gene syndrome [74]. GATA3 haploinsufficiency
is the underlying defect in the HDR syndrome [73] and
BRUNOL3 is a candidate gene for thymus hypoplasia
and possibly for heart defects [75]. Our case 3 is the
first reported case of 10p14 deletion associated with
uterovaginal aplasia. This deletion seems to affect only
the ITIH5 gene, located in the HDR locus, distal to the
GATA3 gene and might account for genital abnormal-
ities associated with renal defects. This suggests that the
ITIH5 gene may be involved in a common mechanism
of renal and genital tract differentiation and that
GATA3 haploinsufficiency independently only causes
renal defects.
Finally, the 22q11.2 deletion is the genetic etiology of
about 90% of cases of DiGeorge syndrome [31]. Six
cases of uterovaginal aplasia have been reported with
22q11.2 deletion. In 1997, Devriendt et al. described a
19-week female fetus with MRKH syndrome, unilateral
renal agenesis, and contralateral multicystic renal dys-
plasia [8]. In 2006, Cheroki et al. analyzed five cases of
uterovaginal aplasia associated with other malformations
by array-CGH: a 22q11.2 deletion (~4 Mb in size) was
detected in a young woman presenting tract genital,
heart, skeletal and facial anomalies but no renal defect
[44]. In the four other cases, uterovaginal aplasia was
associated with unilateral renal agenesis and other mani-
festations (facial anomalies, mild developmental delay,
hypoparathyroïdism, skeletal or heart defect) [45-47].
Here, we report an additional case (case 4) of 22q11.2
deletion associated with uterovaginal aplasia, thymic
hypoplasia, interrupted aortic arch type B, and for the
first time, bilateral renal agenesis. The smallest common
deleted region among the deletions overlapping 22q11.2
Gene
name
Deletedin
MLPA DP/LC
No NA
No No
Yes Yes
NA No
No Na
1 Mb
10p15.3
10p15.2
10p15.1
2 Mb
3 Mb
4 Mb
5 Mb
6 Mb
7 Mb
8 Mb
ADAR3
SFMBT2
ITIH5
ITIH2
GATA3
A B
?
1
?
2
1
?
2
? ? ?
5 6 4 3
5 6 1 2 34
1 3 2
IV
III
II
I
Kidneydefects
Unilateral aplasia
Bilateral aplasia
Uterusdefects
Hemi-uterus
Utero-vaginal aplasia
Abortedfetus
B
Figure 4 Details of the 10p14 deletion in case 3. A. Summary of gene quantification and chromosome breakpoint refinement: several genes
were tested by MLPA (P023 kit) and DP/LC. Combination of the results indicates a heterozygous deletion of about 230 Kb including the ITIH5
gene. NA: Not Applicable. B. Pedigree of the case 3’s family. The proband is indicated with an arrow. Question marks indicate that the
phenotype of putative genetic carriers is unknown.
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is the most frequent ~3 Mb 22q11.2 deletion associated
with DGS [76] (Figure 5). This strongly suggests that
the MURCS association is an additional component of
the 22q11.2 deletion phenotype. However, the genes
within 22q11.2 deletion involved in both renal and uter-
ovaginal anomalies remain to be determined.
Conclusion
The MRKH syndrome is characterized by congenital
uterovaginal aplasia frequently associated with extrage-
nital anomalies (MURCS association). These other
manifestations, such as renal, skeletal and heart malfor-
mations are also found in DGS or DGS-like phenotypes.
Our results show that uterovaginal aplasia can also be
associated with deletions in known DGS (22q11.2) or
DGS-like (4q34-qter, 8p23, and 10p14) loci. These data
suggest that the MURCS association may be an addi-
tional feature of the broad phenotypic spectrum of
DiGeorge syndrome. In the light of this information,
the extent of malformations in cases of either MRKH
syndrome or DGS syndrome should be reconsidered.
Patients with MRKH syndrome, especially MURCS
association, should undergo evaluation of chromosomal
regions responsible of DGS or DGS-like phenotypes.
Similarly, patients diagnosed for DGS syndrome should
be assessed for genital malformations.
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